ReSync Bio to Democratize AI-Powered Drug Discovery with NVIDIA BioNeMo
ReSync Bio, a technology company providing AI-enabled drug discovery solutions, today announced that it has integrated NVIDIA BioNeMo NIM microservices to accelerate its scalable, high throughput AI tools for drug discovery teams. Through this collaboration, ReSync offers seamless, no-code access to the suite of small molecule NVIDIA NIM microservices, empowering drug discovery teams to harness advanced AI without coding expertise.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319575218/en/
Image of the ReSync platform showing the integrated output of a partner model from NVIDIA.
The NVIDIA BioNeMo platform provides state-of-the-art AI tools tailored for drug discovery. Its small molecule NIM microservices, such as GenMol for molecular generation and DiffDock for docking predictions, enable researchers to design, optimize, and evaluate molecules with unprecedented speed and accuracy.
The ReSync platform utilizes NVIDIA NIMs for drug discovery by managing the necessary infrastructure and user interfaces for advanced AI models. Working together with NVIDIA, ReSync has integrated NVIDIA’s core small molecule NIM microservices, DiffDock, MolMIM, and GenMol. Combined with other AI models on ReSync’s platform, including ADME and Toxicity predictions, this collaboration allows users to run a full suite of in-silico analysis throughout the Design - Make - Test - Analyze lifecycle. Teams with limited computational resources can now use ReSync to easily run large-scale virtual screening workflows to quickly explore chemical space.
ReSync’s web platform enables customers to store large volumes of virtual compounds securely, run open-source and custom AI models, and track their experimental progress through synthesis and assays. ReSync’s robust queue management and compute scalability provides customers with industry-leading capabilities for AI-enabled drug discovery, enabling a “lab in the loop” with high throughput virtual screening.
As computational demands grow, ReSync ensures that users can access the necessary resources without worrying about infrastructure management. This scalability allows organizations of any size to leverage the full potential of NVIDIA AI tools while focusing on their core research goals.
“AI has transformed digital drug discovery, but many biotechs and pharma remain limited by their ability to deploy and manage AI infrastructure,” said Mihir Trivedi, CEO of ReSync Bio. “Integrating NVIDIA BioNeMo helps bridge this gap by making advanced AI tools accessible to every drug discovery team—no coding required.”
By integrating NVIDIA’s generative AI capabilities, ReSync is poised to help biotechs accelerate drug discovery timelines and reduce development costs for small molecule therapeutics.
ReSync will be showcasing its platform, including using NVIDIA NIM microservices, at the Bio-IT World Conference & Expo from April 2-4, 2025 in Boston, MA at Booth #209.
To learn more about ReSync or request a trial, fill out our contact form here or book a demo here.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319575218/en/
Contacts
Media Contact:
Mihir Trivedi
media@resync.bio
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RTL Luxembourg Expands Deployment of Verimatrix Technologies to Protect Premier Auto Racing Against Piracy11.9.2025 18:45:00 EEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), a leading provider of security solutions for a safer connected world, today announced that RTL Luxembourg, the country’s leading media company, has further expanded its use of Verimatrix anti-piracy tools to now include the full Streamkeeper suite of solutions. Initially deploying Streamkeeper Multi-DRM, RTL Luxembourg also recently implemented Counterspy, Deepscan and Watermarking solutions – the industry’s latest set of powerful tools that help further bolster proactive protections for RTL’s motorsport content revenue. It was announced in April 2024 that RTL Luxembourg selected Verimatrix Streamkeeper Multi-DRM to ensure that RTL Luxembourg remained in full control of its valuable digital assets while also consistently keeping costs low and preventing unneeded technical complexities. With the addition of Verimatrix’s Counterspy, RTL Luxembourg further expands its ability to detect unauthorized content distribution in real-time, depl
Xylem and Amazon Partner on Smart Water Upgrades to Save More Than 1.3 Billion Liters Annually in Mexico11.9.2025 17:00:00 EEST | Press release
Residents in Mexico City and Monterrey will soon enjoy more reliable water supply as the two cities launch groundbreaking infrastructure upgrades to save over 1.3 billion liters of water a year – easing pressure from the rapid urbanization and persistent drought conditions that have strained local water systems. The two cities are working in partnership with global water technology company Xylem (NYSE: XYL) and Amazon (NASDAQ: AMZN) to deploy Xylem Vue, an advanced software platform that applies data and analytics to detect leaks, cut water losses and improve residents’ water supply. The projects are estimated to save upwards of 800 million liters of water a year in Mexico City and 560 million liters a year in Monterrey. “In a water-stressed region, where every liter counts, recovering more than a billion liters of water each year is a game-changer,” said Jaime Barba, General Manager, Xylem Vue. “Working with Amazon and the local water utilities, we are using data to give these cities
HTEC Partners with World Economic Forum11.9.2025 16:56:00 EEST | Press release
HTEC, a global digital engineering and product development company, has today announced that it has joined the World Economic Forum’s (WEF) Centre for AI Excellence. HTEC will contribute to the community through its expertise and thought leadership to help advance AI adoption and AI innovation across its core industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911910448/en/ HTEC Partners with World Economic Forum to bring AI expertise to help with industry transformation and real-world outcomes WEF’s Centre for AI Excellence is bringing together leading industry organisations and experts to work together to advance the pace and positive impact AI can have in economies and societies. Its goal is to unlock transformative potential in an equitable and human-centered way, which is well aligned with HTEC’s principles and values. As an AI-first organization, HTEC blends deep engineering expertise with strategic insight.
Alipay Tap! Users Reach 200 Million, Expands to Over 1,000 Scenarios Beyond Payments11.9.2025 16:31:00 EEST | Press release
Alipay announced today at the 2025 INCLUSION · Conference on the Bund in Shanghai that its QR code-based contactless payment and engagement solution, Alipay Tap!, has rapidly grown its user base to 200 million since its launch in China in June 2024. The milestone comes just months after surpassing 100 million users in April 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911881010/en/ With Alipay Tap!, users can open a vending machine with a simple tap Designed to be simpler than QR code scanning, Alipay Tap! lets users complete a transaction or access a service by simply tapping their unlocked phone on a merchant’s terminal or Alipay Tap! Tag, eliminating the need to open an app, scan a code, or navigate multiple screens. As Alipay evolves from a digital wallet into a comprehensive platform connecting 1 billion consumers with 80 million merchants nationwide, Alipay Tap! has become a hassle-free gateway to its ecosys
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis11.9.2025 16:05:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.” Dr. Negulescu is one of three awardees, alongside Jesús (Tito) González, a former Vertex scientist, and Michael Welsh, Professor of Internal Medicine-Pulmonary, Critical Care and Occupational Medicine, University of Iowa. The prize honors the groundbreaking work of Dr. Negulescu, Dr. González and the entire Vertex team who discovered and developed the first and only approved medicines that address the underlying cause of CF. To date, Vertex has brought five transformational medicines to patients with CF which have fundamentally changed the way this disease is treated. “I’m hon
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom